Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests
European Journal of Endocrinology · 2024
DOI: 10.1093/ejendo/lvae138 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Chiara Angela Bizzozero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Glycopeptides, Apelin, Polyuria, Arginine Vasopressin. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation.
Abstract (Originalsprache)
Objective
Differentiating between arginine vasopressin deficiency (AVP-D) and primary polydipsia (PP) requires a copeptin stimulation test. We aimed to characterize changes in apelin, an endogenous hormone antagonizing AVP, upon copeptin stimulation tests.
Design
Post hoc secondary analysis of a multi-centric cross-over diagnostic study (NCT03572166).
Setting
Outpatients included at the University Hospital Basel.
Participants
Patients with AVP-D and PP.
Interventions
Copeptin stimulation tests with hypertonic saline and arginine infusion. Outcomes and Measures The primary outcome was the absolute difference in apelin between baseline and peak of copeptin stimulation tests. Secondary objectives included the diagnostic ability of apelin.
Results
Thirty-eight patients were analysed, 23 (60%) had PP and 15 (40%) had AVP-D. No difference was seen between baseline median (IQR) apelin levels in PP and AVP-D (1079 [912, 1225] and 910 [756, 1039] pmol/L, respectively). Upon hypertonic saline, apelin decreased by −241 (−326, −124) pmol/L in PP and −47.2 (−198, 5.86) pmol/L in AVP-D (P = .022). The area under the curve (AUC) to differentiate PP from AVP-D was 97.1% (95% CI, 90.5-100) for copeptin and 49.3% (95% CI, 30.4-68.1) for apelin (P < .001). Upon arginine, apelin decreased by −39.2 (−96.4, 39.8) pmol/L in PP and increased by 25.8 (2.8, 113.0) pmol/L in AVP-D (P = .1). The AUC was 97.1% (95% CI: 79.6-98.0) for copeptin and 60.5% (95% CI: 39.8-80.0) for apelin (P = .007). Conclusions and Relevance Our findings suggest that apelin decreases to a greater extent in PP compared with AVP-D upon copeptin stimulation tests. However, copeptin remains the best marker to differentiate AVP-D from PP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.
- Department of Clinical Research, University of Basel, Basel, Switzerland.
- BHF/University Centre for Cardiovascular Science, The Queen's Medical Research Institute, Edinburgh, United Kingdom.
- Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
ORCID-Profile: Chiara Angela Bizzozero, Sophie Monnerat, Fiona A Chapman, Neeraj Dhaun, Julie Refardt, Mirjam Christ-Crain
Förderung
- Swiss National Science Foundation
Zitieren
APA
Bizzozero, C. A., Monnerat, S., Chapman, F. A., Dhaun, N., Refardt, J., & Christ-Crain, M. (2024). Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae138
Vancouver
Bizzozero CA, Monnerat S, Chapman FA, Dhaun N, Refardt J, Christ-Crain M. Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae138
BibTeX
@article{Bizzozero2024,
author = {Bizzozero, Chiara Angela and Monnerat, Sophie and Chapman, Fiona A and Dhaun, Neeraj and Refardt, Julie and Christ-Crain, Mirjam},
title = {Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests},
journal = {European Journal of Endocrinology},
year = {2024},
doi = {10.1093/ejendo/lvae138}
}
EUVIMED